Search

Displaying results 2491 - 2500 of 10000 in total
  1. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.

  2. Drug

    Amphotericin B

    go.drugbank.com/drugs/DB00681
    ApprovedInvestigational

    The antibiotic is without effect on bacteria, rickettsiae, and viruses. … Amphotericin B shows a high order of in vitro activity against many species of fungi.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Urea C-13

    go.drugbank.com/drugs/DB09510
    ApprovedInvestigational

    Radiolabelled urea is available in two forms as 13C and 14C. … As the urease enzyme is not present in mammalian cells, the presence of urease (and the products of urea cleavage) in the stomach is evidence that H. pylori bacteria are present.

  4. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be … [L50903] It works to induce bronchodilator and reduce inflammation in COPD.[A263913]

    Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-
  5. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]

  6. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.

  7. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

  8. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  9. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy.

  10. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]